Dr. David Nierengarten


Image: Dr. David Nierengarten

David Nierengarten is an analyst covering stocks in the biotechnology sector. His prior sellside research experience at Robert W. Baird & Co. covered biotechnology companies of all market capitalizations, with a focus on oncology and rare diseases. Nierengarten's prior early-stage venture capital investing experience helps him evaluate developmental-stage biotechnology companies that comprise his current major coverage focus. His experience on the other side of that equation, in a clinical-stage, venture-backed biotechnology company, provides him with additional insights into corporate operations. He received his bachelor's degree in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular and cell biology from the University of California Berkeley.

Recent Articles

Biotech Bolsters ADC Pipeline Through Atreca Asset Buy 12/26/2023

Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush.

Massachusetts Biotech Presents Catalysts Into 2024 11/08/2023

Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.

Firm To Present Trial Results Update at SITC Meeting 11/02/2023

Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.

Recent Quotes

"SNSS does have a path forward in Europe, where it has a shot at approval for Qinprezo."

The Life Sciences Report Interview with David Nierengarten (8/26/15)
more >

Due to permission requirements, not all quotes are shown.